Latest News

Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden
Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden

March 27th 2025

A new analysis reveals significant gaps in diagnosis of and treatment for psychiatric disorders in adults with COPD and calls for larger, longitudinal studies.

Long COVID's Long Road: A Year-5 Update with Noah Greenspan DPT, PT, CCS, EMT-B
Long COVID's Long Road: A Year 5 Update with Noah Greenspan DPT, PT, CCS, EMT-B

March 26th 2025

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose / image credit: ©New Africa/AdobeStock
Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose

March 24th 2025

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose / image credit: ©New Africa/AdobeStock
Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose

March 20th 2025

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

March 10th 2025

Video Interviews
Podcasts
Latest CME Events & Activities

Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®

View More

Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care

View More

Charting the Path to Precision Diagnosis: Detection and Treatment Approaches for Oncogenic Mutations in NSCLC

View More

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

April 4, 2025 | New York, NY & Virtual

Register Now!

Community Practice Connection™: 21st Annual Winter Lung Cancer Conference®

View More

Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights Into Predicting Pathologic Responses to Immunotherapies

View More

BURST CME™: How Are Emerging Biomarkers and Testing Methodologies Shaping Personalized Medicine in NSCLC?

View More

Navigating Current State-of-the Art NSCLC Patient Care From the Front Lines: Essentials for Oncology Nurses Today and Tomorrow

View More

Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?

View More

Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

DLL3 as a Therapeutic Target in SCLC and Beyond: Rationale, Recent Data and Potential for Transformations in Care with T-Cell Engagers

View More

Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension

View More

Advances In™: Moving Care Forward in SCLC with DLL3 Targeting Bispecific T-Cell Engagers

View More

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

View More

What’s Next for HER2- and TROP2-Directed ADCs in Lung Cancer: How Emerging Trial Data will Impact our Clinics Today, and Tomorrow….

View More

Do We Have Sea Change in Small Cell Lung Cancer? What Recent Clinical Trial Data Tell Us About Treatment Decision-Making in Real-World Settings, What’s Next for Emerging Novel Strategies

View More

Community Practice Connections™: 25th Annual International Lung Cancer Congress

View More

Community Practice Connections™: 8th Annual School of Nursing Oncology™

View More

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

View More

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

View More

(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

View More

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

View More

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

View More

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

Virtual Tumor Board for the Onco-Nurse: Improving Outcomes in SCLC Treatment and AE Management

View More

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

View More

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

View More

More News

© 2025 MJH Life Sciences

All rights reserved.